CHICAGO, May 15, 2025--(BUSINESS WIRE)--MAIA Biotechnology ... from the Phase 2 THIO-101 clinical trial was accepted for poster presentation at the 2025 Annual Meeting of the American Society ...

PanGIA Biotech, a company advancing urine-based ... using urine-based liquid biopsy (Abstract #3080), has been accepted for presentation in the poster session titled Developmental Therapeutics ...

PRINCETON, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation ... have been accepted for presentation at the 2025 American Society of Clinical Oncology (“ASCO”) Annual ...

Siren Biotechnology Inc., pioneers of Universal AAV Immuno-Gene Therapy for Cancer, today announced that it will present new scientific data at the 2025 American Society of Gene and Cell Therapy ...

Adagene Inc. announced a poster presentation for the ASCO 2025 conference ... which can enhance visibility and credibility within the biotechnology community. The updated results of the Phase ...

BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through its contractual relationship with BioDuro-Sundia, a provider of ...

The poster presentations will include preclinical ... and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements ...

CHICAGO, May 15, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American ... the efficacy data from the Phase 2 THIO-101 clinical trial was accepted for poster presentation at the 2025 Annual ...

today announced that an abstract co-authored by researchers from PanGIA Biotech, Entopsis Inc., and Genetics Institute of America has been accepted for presentation at the 2025 Annual Meeting of ...